Anti-Plasminogen antibody [5H3] (ab10173)

Overview

  • Product nameAnti-Plasminogen antibody [5H3]
    See all Plasminogen primary antibodies
  • Description
    Mouse monoclonal [5H3] to Plasminogen
  • SpecificityReacts with plasminogen, plasmin and angiostatin.
  • Tested applicationsSuitable for: ELISA, IHC-P, Sandwich ELISA, Othermore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified) (Human).

  • General notesConcentration varies from lot to lot and can be provided on request.

Properties

Applications

Our Abpromise guarantee covers the use of ab10173 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
AP
IHC-P
Sandwich ELISA
Other
  • Application notesAP: Use at an assay dependent dilution.
    ELISA: Use at an assay dependent dilution.
    IHC-P: Use at an assay dependent dilution. Antigen retrieval is not essential but may optimise staining.
    sELISA: Can be used in sandwich ELISA with Plasminogen antibody [8E7] (HRP) (ab10176)(conjugate). Use at an assay dependent dilution.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionPlasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
      Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
    • Tissue specificityPresent in plasma and many other extracellular fluids. It is synthesized in the liver.
    • Involvement in diseaseDefects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
      Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
    • Sequence similaritiesBelongs to the peptidase S1 family. Plasminogen subfamily.
      Contains 5 kringle domains.
      Contains 1 PAN domain.
      Contains 1 peptidase S1 domain.
    • DomainKringle domains mediate interaction with CSPG4.
    • Post-translational
      modifications
      N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
      In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
    • Cellular localizationSecreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
    • Information by UniProt
    • Database links
    • FormCleaved into the following 5 chains: 1.Plasmin heavy chain A2.Activation peptide3.Angiostatin4.Plasmin heavy chain A, short form5. Plasmin light chain B
    • Alternative names
      • Angiostatin antibody
      • DKFZp779M0222 antibody
      • Plasmin antibody
      • Plasmin heavy chain A antibody
      • Plasmin light chain B antibody
      • Plasminogen antibody
      • PLG antibody
      • PLMN_HUMAN antibody
      see all

    References for Anti-Plasminogen antibody [5H3] (ab10173)

    ab10173 has not yet been referenced specifically in any publications.

    Product Wall



    J'ai parcouru les différents monoclonaux anti-plasminogen de notre catalogue, les 2 seuls anticorps fournis en PBS pure sont ab80728 et ab20230, qui reconnaissent tous les 2 le plasminogène et plasmine mais pas HGF1/MPS ou HGF/S...

    Read More

    Thank you very much for your email and patience. All the information that we have regarding these antibodies is located on the online datasheets. At this time, we don't have any information concerning the epitopes. For ELISA, ab10176 can be used as con...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"